Tirzepatide
€299.00
Productinformation
3ml cartridge with 10mg tirzepatide
Expiration date: 01-11-2027
Pen delivers doses of 0.5, 1, 1.5, 2 or 2.5mg.
3ml cartridge with 40mg tirzepatide
Expiration date: 01-12-2027
Pen delivers 4x10mg.
1mg 6 clicks, 2mg 12 clicks, 5mg 30 clicks, 10mg 60 clicks.
Keep in the fridge between 3 and 7 °C.
Use only 8 weeks after first dose.
Dosing schedule
Start: 1-2 mg per week
Then: increase step by step.
Possible doses are: 1 – 2 – 4 – 8 – 12 mg per week
Maximum dose: 12 mg per week
“The goal is to find the right balance between minimizing side effects and achieving sufficient appetite suppression. So the dose can be lower than suggested”
Tirzepatide is a next-generation treatment for obesity, developed as a dual GLP-1 and GIP receptor agonist. By simultaneously activating these pathways in the brain and gut, it enhances insulin secretion, reduces appetite, and slows gastric emptying—leading to decreased calorie intake and substantial weight loss.
Clinical trials have demonstrated remarkable outcomes, with an average weight loss of up to 22.5% over 72 weeks, compared to 2.4% with placebo. Preclinical and neuroimaging studies further confirm its effects on appetite regulation, satiety, and energy balance.
Beyond weight reduction, tirzepatide significantly improves cardiometabolic health, lowering blood pressure, improving lipid profiles, and enhancing insulin sensitivity. By addressing multiple metabolic dysfunctions at once, it offers a more comprehensive strategy for obesity and related conditions such as type 2 diabetes.
Real-world evidence increasingly supports its long-term safety and effectiveness across diverse patient groups, positioning tirzepatide as one of the most promising and scientifically validated solutions in the fight against obesity.
The pen comes with a clear instruction flyer. According to our customers, this makes the pen easy to use.
Weight Loss Pen Europe GmbH
Biocampus München
82152 Martinsried
Germany